160 related articles for article (PubMed ID: 37321329)
1. Accelerated reactive dissolution model of drug release from long-acting injectable formulations.
Sonntag E; Kolář J; Djukaj S; Lehocký R; Štěpánek F
Eur J Pharm Biopharm; 2023 Aug; 189():122-132. PubMed ID: 37321329
[TBL] [Abstract][Full Text] [Related]
2. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
Darville N; van Heerden M; Mariën D; De Meulder M; Rossenu S; Vermeulen A; Vynckier A; De Jonghe S; Sterkens P; Annaert P; Van den Mooter G
J Control Release; 2016 May; 230():95-108. PubMed ID: 27067365
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats.
Darville N; van Heerden M; Vynckier A; De Meulder M; Sterkens P; Annaert P; Van den Mooter G
J Pharm Sci; 2014 Jul; 103(7):2072-2087. PubMed ID: 24845884
[TBL] [Abstract][Full Text] [Related]
4. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
[TBL] [Abstract][Full Text] [Related]
5. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
7. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
[TBL] [Abstract][Full Text] [Related]
8. Long-Acting Diclofenac Ester Prodrugs for Joint Injection: Kinetics, Mechanism of Degradation, and In Vitro Release From Prodrug Suspension.
Mertz N; Larsen SW; Kristensen J; Østergaard J; Larsen C
J Pharm Sci; 2016 Oct; 105(10):3079-3087. PubMed ID: 27475785
[TBL] [Abstract][Full Text] [Related]
9. Use of mesoporous cellular foam (MCF) in preparation of polymeric microspheres for long acting injectable release formulations of paliperidone antipsychotic drug.
Nanaki S; Tseklima M; Terzopoulou Z; Nerantzaki M; Giliopoulos DJ; Triantafyllidis K; Kostoglou M; Bikiaris DN
Eur J Pharm Biopharm; 2017 Aug; 117():77-90. PubMed ID: 28389342
[TBL] [Abstract][Full Text] [Related]
10. [Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
Kyziridis TC
Psychiatriki; 2022 Jun; 33(2):139-148. PubMed ID: 34390562
[TBL] [Abstract][Full Text] [Related]
11. Microcrystals of Ketal-Linked Paliperidone Prodrugs for Long-Acting Antipsychotics.
Xu Z; Liu T; Jiang Y; Chen Z; Shi X; Xu Y; Yu N; Hua X; Liang XJ; Yuan X; Guo S
Mol Pharm; 2022 Nov; 19(11):3846-3857. PubMed ID: 36047719
[TBL] [Abstract][Full Text] [Related]
12. Interpreting
Rudd ND; Reibarkh M; Fang R; Mittal S; Walsh PL; Brunskill APJ; Forrest WP
Mol Pharm; 2020 May; 17(5):1734-1747. PubMed ID: 32267708
[TBL] [Abstract][Full Text] [Related]
13. Impact of Formulation Parameters on In Vitro Release from Long-Acting Injectable Suspensions.
Bao Q; Zou Y; Wang Y; Choi S; Burgess DJ
AAPS J; 2021 Mar; 23(2):42. PubMed ID: 33709196
[TBL] [Abstract][Full Text] [Related]
14. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
15. Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs.
Bettonte S; Berton M; Battegay M; Stader F; Marzolini C
CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):781-794. PubMed ID: 38429889
[TBL] [Abstract][Full Text] [Related]
16. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
17. Multimodal non-linear optical imaging for the investigation of drug nano-/microcrystal-cell interactions.
Darville N; Saarinen J; Isomäki A; Khriachtchev L; Cleeren D; Sterkens P; van Heerden M; Annaert P; Peltonen L; Santos HA; Strachan CJ; Van den Mooter G
Eur J Pharm Biopharm; 2015 Oct; 96():338-48. PubMed ID: 26347923
[TBL] [Abstract][Full Text] [Related]
18. Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.
Krovi SA; Gallovic MD; Keller AM; Bhat M; Tiet P; Chen N; Collier MA; Gurysh EG; Pino EN; Johnson MM; Shamim Hasan Zahid M; Cottrell ML; Pirone JR; Kashuba AD; Kwiek JJ; Bachelder EM; Ainslie KM
Int J Pharm; 2018 Dec; 552(1-2):371-377. PubMed ID: 30308272
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of long-acting antipsychotic medications.
Spanarello S; La Ferla T
Curr Clin Pharmacol; 2014; 9(3):310-7. PubMed ID: 23343447
[TBL] [Abstract][Full Text] [Related]
20. Model for Long Acting Injectables (Depot Formulation) Based on Pharmacokinetics and Physical Chemical Properties.
Shah JC; Hong J
AAPS J; 2022 Mar; 24(3):44. PubMed ID: 35298711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
